GRACE :: Breast Cancer


Dr Cianfrocca

Is One Year of Adjuvant Herceptin for Early Stage Breast Cancer Really Optimal?


Since the FDA approval of Herceptin in the adjuvant setting for HER2-positive, early stage breast cancer, one year of Herceptin has been the standard length of therapy. This was based on the design of multiple, large, randomized trials that were published in 2005. Many people, however, argued that the choice of one year was not based on scientific data, and that is was somewhat arbitrary. Two studies presented at the 2012 Congress of the European Society for Medical Oncology (ESMO) in Vienna this past week, however, supported the belief that one year of therapy is optimal. In the two studies presented at ESMO, investigators evaluated both shorter and longer durations of Herceptin treatment.

Continue reading

Molecular Subtypes of Breast Cancer


Breast cancer is a remarkably diverse disease.  In terms of gene expression there are multiple different molecular subtypes of breast cancer.  Dr. Chuck Perou and his colleagues demonstrated that the way an individual breast cancer behaved was associated with differences in the expression of various genes in the tumor. From the genes in the tissue samples, they selected a subset of 456 genes which they named the “intrinsic” gene subset. This subset contained genes that were significantly different among different breast cancers. Using this subset, they were then able to identify 5 very different molecular subtypes of breast cancer:

  • ER-positive/luminal A
  • ER-positive/luminal B
  • Basal-like
  • HER2-positive
  • Normal breast

These five molecular subtypes have been confirmed in independent data sets, and importantly, the individual gene expression subtype appears to remain consistent between the original tumor and subsequent metastatic lesions occurring years later.  Furthermore, these subtypes are associated with differences in clinical outcome. Sorlie and his colleagues examined a subset of 49 locally advanced breast cancers that had been treated with adriamycin and found that both relapse-free (RFS) and overall survival (OS) differed significantly among the breast cancer subtypes.  Luminal A tumors had the longest survival times, the basal-like and HER2+/ER- subtypes had the shortest survival times and the luminal B tumors had intermediate survival times

Continue reading

New Targeted Therapy approved for ER-positive, HER2-negative Breast Cancer: Afinitor with Aromasin


On July 20, 2012, the U.S. Food and Drug Administration (FDA) gave us another option for treating postmenopausal patients with metastatic, ER-positive, HER2-negative breast cancer whose disease has progressed on Arimidex or Femara by approving Afinitor (everolimus) in combination with Aromasin (exemestane). This new approval was based on the BOLERO-2 trial which was a randomized, double-blind, multicenter trial conducted in 724 postmenopausal women.  Patients were randomized to receive either Afinitor 10 mg/day plus Aromasin 25 mg/day or to placebo plus Aromasin 25 mg/day. Both Aromasin and Afinitor are oral drugs.

Aromasin is an aromatase inhibitor which works by lowering estrogen levels in postmenopausal women. This trial was based on the observation that resistance (either not responding or stopping responding) to hormonal therapy is associated with a tumor being able to use pathways other than the estrogen pathway to survive and grow. One example of this is activation of the mammalian target of rapamycin (mTOR) signaling pathway in cells. Afinitor targets the mTOR pathway and is classified as an mTOR inhibitor. 

On the BOLERO-2 trial, the median progression-free survival (PFS) was longer for the patients receiving Afinitor (7.8 vs 3.2 months). These results were consistent regardless of age, race, presence or extent of visceral metastases (such as liver metastases), and response to prior hormonal therapy.  The response rate was also better for the patients receiving Afinitor (12.6% vs 1.7%).  The analysis of overall survival (OS) was not significant however this was an interim analysis.  The final OS analysis isn’t expected to become available until June, 2014.

Continue reading

Perjeta (Pertuzumab) Approved by FDA for HER2-Positive Advanced Breast Cancer


On June 8, The U.S. Food and Drug Administration (FDA) approved Perjeta (pertuzumab) to treat patients with metastatic, HER2-positive breast cancer who have not received previous treatment with either chemotherapy or HER2-targeted therapy. Approximately 20-30% of breast cancer is HER2-positive.

Herceptin is a monoclonal antibody that works by blocking HER2. While Perjeta also targets HER2, it binds to a different area of the HER2 protein and prevents the HER2 protein from combining with other HER receptors (HER1, HER3, and HER4). This prevents tumor growth and survival. Perjeta’s mechanism of action is therefore believed to be complimentary to that of Herceptin. In fact, Perjeta by itself has very little activity; its real use is in combination with Herceptin.

Continue reading

Antibody-Drug Conjugate T-DM1 Offers New Mechanism and Significant Benefit in HER2-Positive Breast Cancer


Right at the top of the list of the most exciting news from the 2012 American Society of Clinical Oncology (ASCO) meeting in Chicago this week involved using T-DM1 to treat metastatic, HER2-positive breast cancer.  T-DM1 is an “antibody-drug conjugate” (ADC).

ADCs combine a tumor-specific antibody with a chemotherapy drug. They are therefore specifically designed to be able to deliver chemotherapy drugs directly to tumor cells (like a “smart bomb”), potentially increasing efficacy and decreasing damage to normal cells. T-DM1 combines the anti-HER2 antibody Herceptin (trastuzumab), a stable linker and a chemotherapy agent, DM1, also known as emtansine.

Befitting its importance, the EMILIA trial was presented at the high profile Plenary Session. In this study almost 1000 patients with metastatic, HER2-positive breast cancer whose disease had progressed after treatment with a taxane and Herceptin were randomized to receive Xeloda (capecitable) plus Tykerb (HER2-inhibiting tyrosine kinase inhibitor lapatinib) or T-DM1. Xeloda and Tykerb are oral drugs; the T-DM1 was given intravenously every 3 weeks. There was no “cross-over”, meaning that patients whose disease progressed on Xeloda and Tykerb did not have access to T-DM1.

Continue reading

Ask Us, Q&A
Breast Cancer Expert Content



GRACE Cancer Video Library - Lung Cancer Videos




2015 Acquired Resistance in Lung Cancer Patient Forum Videos


Join the GRACE Faculty

Lung/Thoracic Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog

Subscribe to the GRACEcast Podcast on iTunes


Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
   (Free Newsletter)

Other Resources


Biomedical Learning Institute